The identification and treatment of individuals with tuberculosis (TB) is a global public health priority. Accurate diagnosis of pulmonary active TB (ATB) disease remains challenging and relies on extensive medical evaluation and detection of Mycobacterium tuberculosis (Mtb) in the patient's sputum. Further, the response to treatment is monitored by sputum culture conversion, which takes several weeks for results. Here, we sought to identify blood-based host biomarkers associated with ATB and hypothesized that immune activation markers on Mtb-specific CD4 + T cells would be associated with Mtb load in vivo and could thus provide a gauge of Mtb infection.
Introduction
Diagnosis of pulmonary active tuberculosis (ATB) currently relies on evaluation of clinical symptoms, radiological assessments,and detection of Mycobacterium tuberculosis (Mtb) in patient respiratory samples, such as sputum. Microscopic detection of Mtb in sputum smears is the most widely used method for diagnosing pulmonary ATB and for monitoring response to treatment (1) . However, sputum smears are poorly sensitive and a high proportion (20%-66%) of tuberculosis (TB) cases are smear negative (2) . Nucleic acid amplification-based tests are more sensitive for diagnosing ATB (2), but do not differentiate between live and dead Mtb and are thus not useful for monitoring treatment-mediated clearance of Mtb. Sputum culture is currently the gold standard for TB diagnosis and for monitoring treatment response, but takes 3 to 6 weeks for results (1) . Blood-based host biomarkers for diagnosing TB are attractive alternatives to tests that rely on detecting mycobacteria. Existing blood-based tests, such as IFN-γ release assays (IGRAs), measure IFN-γ + production in response to stimulation with Mtb-specific antigens ESAT6 and CFP10 and are specific for Mtb infection (3, 4) . However, IGRAs (e.g., QuantiFERON or T-SPOT.TB) fail to discriminate between ATB and latent Mtb infection (LTBI) (5, 6) and are inadequate for monitoring treatment response (7) . Since CD4 + T cells are the predominant cell type producing IFN-γ in response to Mtb infection (8), we hypothesized that host immune markers on Mtb-specific CD4 + T cells that correlate with pathogen load could confer discriminatory capacity to IFN-γ-based assays.
Studies in chronic viral infections have shown that the phenotypes and frequencies of virus-specific CD4 + and CD8 + T cell phenotypes correlate with viral antigen load in vivo (9, 10) . Due to the large burden of replicating mycobacteria present in ATB BACKGROUND. The identification and treatment of individuals with tuberculosis (TB) is a global public health priority. Accurate diagnosis of pulmonary active TB (ATB) disease remains challenging and relies on extensive medical evaluation and detection of Mycobacterium tuberculosis (Mtb) in the patient's sputum. Further, the response to treatment is monitored by sputum culture conversion, which takes several weeks for results. Here, we sought to identify blood-based host biomarkers associated with ATB and hypothesized that immune activation markers on Mtb-specific CD4 + T cells would be associated with Mtb load in vivo and could thus provide a gauge of Mtb infection.
METHODS.
Using polychromatic flow cytometry, we evaluated the expression of immune activation markers on Mtb-specific CD4 + T cells from individuals with asymptomatic latent Mtb infection (LTBI) and ATB as well as from ATB patients undergoing anti-TB treatment.
RESULTS. Frequencies of Mtb-specific IFN-γ + CD4
+ T cells that expressed immune activation markers CD38 and HLA-DR as well as intracellular proliferation marker Ki-67 were substantially higher in subjects with ATB compared with those with LTBI. These markers accurately classified ATB and LTBI status, with cutoff values of 18%, 60%, and 5% for CD38 , respectively, with 100% specificity and greater than 96% sensitivity. These markers also distinguished individuals with untreated ATB from those who had successfully completed anti-TB treatment and correlated with decreasing mycobacterial loads during treatment.
CONCLUSION.
We have identified host blood-based biomarkers on Mtb-specific CD4 + T cells that discriminate between ATB and LTBI and provide a set of tools for monitoring treatment response and cure. TRIAL REGISTRATION. Registration is not required for observational studies.
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Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response + T cells each distinguished individuals with LTBI from treatmentnaive individuals with sputum culture-confirmed ATB recruited from the metropolitan Atlanta area (Georgia, USA). These markers also accurately classified individuals with ATB and LTBI recruited from the Western Cape in South Africa. Finally, we show that these markers are associated with responsiveness to anti-TB treatment and clinical resolution of TB.
Results

Higher frequencies of Mtbspecific CD4
+ T cells expressing CD38, HLA-DR, and Ki-67 in subjects with ATB compared with LTBI. We recruited individuals with LTBI and ATB in the metropolitan Atlanta area (Figure 1 ). LTBI subjects were identified based on a positive response to the Mtb-specific antigens ESAT6 and CFP10 upon screening their peripheral blood mononuclear cells (PBMCs) by IFN-γ ELISPOT assays as previously described (18) . Patients with sputum culture-confirmed pulmonary TB disease were recruited at Grady Memorial Hospital prior to initiation of anti-TB treatment (Supplemental Tables 1 and 2 ; supplemental material available online with this article; doi:10.1172/JCI77990DS1). As indicated in Figure 1, only patients with detectable IFN-γ responses to ESAT6/ CFP10 peptide pools, as measured by flow cytometry, were included in the study. All 26 sputum-positive patients showed responses to cell wall (CW) antigens; of these, only 24 had detectable ESAT6/CFP10 responses. We then assessed the activation profile of Mtb-specific CD4 + T cells in these 24 ATB patients and (11), we reasoned that individuals with ATB would harbor higher proportions of Mtb-specific CD4 + T cells with an activated phenotype than those with LTBI, in whom the immune response controls infection. We focused on 3 molecules described in several studies as markers of activated, proliferating T cells (12) (13) (14) . Human CD38 is a transmembrane glycoprotein that is expressed in a wide array of immune cell types. CD38 has ectoenzyme properties, catalyzing the synthesis and hydrolysis of NAD or cyclic ADP-ribose, and its expression is highly induced on the surface of antigen-specific effector T cells. HLA-DR is an MHC class II cell-surface receptor (12) (13) (14) and correlate with response to antiretroviral therapy (20) . To determine whether Mtb-specific CD38 + T cells correlated with response to treatment and mycobacterial load, we performed longitudinal studies of sputum-positive pulmonary ATB patients with drug-susceptible TB (n = 10) who were enrolled prior to initiation of treatment and followed during and after successful completion of treatment (Figure 1) . We assessed frequencies of CD38 
CD4
+ T cells as biomarkers for ATB. To assess the accuracy of these markers in predicting ATB and LTBI status, we performed receiver operating characteristic (ROC) analysis (19) in the test cohort. Supplemental Figure  2 + T cells in an independent cohort from South Africa. To explore the utility of measuring the frequencies of Mtb-specific CD4 + T cells expressing CD38, HLA-DR, and Ki-67 and their respective cutoff values as diagnostic biomarkers for ATB, we examined PBMCs from an independent validation cohort from the Western Cape in South Africa. Individuals with ATB and LTBI were recruited as described in Methods and in Supplemental  Table 3 . The investigators were blinded to the clinical diagnoses + T cells expressing CD38, HLA-DR, and Ki-67 were significantly lower (P < 0.0001) in the treated ATB group compared with individuals with untreated ATB and reached or approached frequencies seen in the LTBI group (Figure 8, A-C) . This IFN-γ + T cells remained unchanged ( Figure 7A ). This reflected decreasing bacterial burdens, as evidenced by sputum smear and culture conversion at 2 months. Similar results were seen when the data were expressed as median fluorescence intensity (MFI) ( Figure 6C ). These trends were observed for all 10 patients studied (P1-P10; Figure 7A ), suggesting that decreases in the frequencies of Mtb-specific CD4 + T cells expressing CD38, HLA-DR, or Ki-67 are associated with treatment response in patients with drug-susceptible TB. Notably, while patients P4 and P5 were smear negative at day 45, they remained culture positive and had higher than cutoff values for the host markers studied ( Figure 7A ), confirming the relative imprecision of smears for monitoring treatment and highlighting greater sensitivity of culture and host markers for assessing Mtb clearance during treatment.
The standard treatment regimen for drug-susceptible TB consists of a 2-month intensive phase with isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE), followed by a 4-month continuation phase with isoniazid and rifampicin (HR) (21) . Conversion to a negative sputum culture at 2 months after treatment initiation is currently the most objective indicator of response to treatment [24] [25] [26] . Moreover, humans with IFN-γ receptor abnormalities show increased susceptibility to mycobacterial diseases (27) . However, IFN-γ responses are not indicative of immune control in TB, and Mtb-specific IFN-γ + CD4 + T cells do not distinguish between active and latent TB. Our study highlights the inability of Mtb-specific IFN-γ production or CD38, HLA-DR, and Ki-67 expression on bulk CD4
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+ T cells to discriminate between ATB and LTBI and monitor decreasing bacterial loads. This is consistent with previous studies (28) (29) (30) and underscores the utility of phenotypic markers expressed on Mtb-specific CD4 + T cells as biomarkers for diagnosing TB. We chose to study markers of immune activation and proliferation on Mtb-specific CD4 + T cells because we reasoned that individuals with ATB disease would harbor higher frequencies of activated (CD38 + , HLA-DR + ), cycling (Ki-67 + ) T cells than those with LTBI. We have previously shown that Mtb-specific effector memory CD4 + T cells in individuals with LTBI exhibited a resting, nonactivated phenotype and were largely noncycling (18) . In the present study, we have identified the immune activation markers CD38 and HLA-DR and the intracellular proliferation marker Ki-67 on Mtb-specific IFN-γ + CD4 + T cells as biomarkers that discriminate between ATB and LTBI with high sensitivity, specificity, and predictive value in a US-based cohort. We further validated the ability of these biomarkers to accurately classify ATB and LTBI in an independent cohort from South Africa, where the investigators were blinded to the clinical diagnoses until after completion of the laboratory analyses. Thus, our studies have identified phenotypic biomarkers that provide discriminatory capacity to IFN-γ + -based assays. While we found that CD38, HLA-DR, and Ki-67 expression on Mtb-specific CD4 + T cells distinguished individuals with LTBI from ATB patients, examining expression levels of these biomarkers on Mtb-specific CD8 + T cells was less useful. This is due to low-to-undetectable frequencies of CD8 + IFN-γ + T cells in individuals with LTBI and ATB (Supplemental Figure  4) , consistent with previous reports (22, (31) (32) (33) (34) . Thus, unlike with CD4 + IFN-γ + T cells, phenotyping the CD8 + IFN-γ + T cells for expression of CD38, HLA-DR, and Ki-67 was not possible for the majority of LTBI samples. Therefore, Mtb-specific CD4 + T cells provided the optimal biomarker signatures.
We also show that frequencies of CD38-, HLA-DR-, and Ki-67-expressing Mtb-specific CD4 + T cells correlate with + T cells, which mirrored culture conversion. Currently, assessing the adequacy of treatment by sputum culture is hindered by long incubation times (1). Our data suggest that measuring host immune markers by flow cytometry-based tests may prove to be useful for monitoring treatment response by providing a more rapid indicator of Mtb load in vivo.
Discussion
CD4
+ T cells expressing IFN-γ + clearly play a critical role in controlling Mtb replication and containing bacteria within lung gran- Mtb burden in vivo and mirror sputum conversion during anti-TB treatment, providing real-time readouts for monitoring a patient's responsiveness to treatment. Our observations in TB are similar to studies in HIV-infected individuals, where CD8 + T cells expressing CD38 and HLA-DR were shown to be associated with persistent immune activation, correlated with HIV viral load in peripheral blood, and decreased in response to antiretroviral therapy (35, 36) . One of the limitations of our study is that we restricted our analyses in the test cohort to ATB patients who exhibited detectable responses to both Mtb-CW antigens and to ESAT6/CFP10 peptide pools. Thus, we excluded patients who were responsive to Mtb-CW but not to ESAT6/CFP10 peptide pools. This is a general limitation of immune-based assays that measure Mtb-specific responses. IFN-γ production (i.e., IGRAs) in response to ESAT6/CFP10 stimulation has been shown in recent meta-analyses to have a pooled sensitivity of approximately 80% for TB cases and their contacts in endemic and nonendemic settings (37) (38) (39) . The use of additional, highly immunogenic Mtb-specific antigens could potentially improve the performance of immune-based assays in patients in whom there is a lack of detectable ESAT6/CFP10 responses. TB-specific host biomarkers for diagnosis of ATB and monitoring treatment response have been identified as important priorities for TB research (40) and have been explored in some recent studies. Berry et al. identified an IFN-inducible neutrophil-driven transcriptional signature that was associated with ATB disease and correlated with response to treatment (41) . Similar transcriptional blood signatures were shown to distinguish pulmonary TB from pulmonary sarcoidosis, pneumonias, and lung cancer (42) . Since these signatures were derived from total unstimulated blood cell populations, the discriminatory capacity of phenotypic markers on Mtb-specific T cells could not be determined in these studies. Other studies evaluated frequencies of single and polyfunctional cytokine-producing Mtb-specific T (28, 43) . Expression of the costimulatory molecule CD27 on Mtb-specific T cells was recently shown to have predictive value in distinguishing active and latent TB; however, CD27 + IFN-γ + CD4 + T cell frequencies were not evaluated in the context of monitoring treatment response in longitudinal studies (44) (45) (46) .
We found that frequencies of CD38 + IFN-γ + , HLA-DR + IFN-γ + , and Ki-67 + IFN-γ + Mtb-specific T cells were comparable to those in the LTBI group in all 10 patients who successfully resolved TB clinical response to treatment is currently used as diagnosis (47) . While the 6-month treatment duration is recommended as the standard regimen for treating ATB, longer regimens are required when sputum conversion is delayed beyond the 2-month milestone. In this context, blood-based biomarkers have the potential after 6 months of anti-TB treatment. Our data also showed that these biomarkers correlated with Mtb load and mirrored sputum conversion during the course of anti-TB treatment, suggesting that these biomarkers may also prove useful for diagnosing culture-negative individuals with clinical symptoms of TB, for whom 
+ T cells show potential as biomarkers for diagnosing ATB. Moreover, they provide a gauge of Mtb load in vivo, suggesting utility as surrogate markers of treatment response and as predictors of treatment efficacy, cure, and relapse in patients undergoing anti-TB treatment for drug-susceptible as well as drugresistant TB and in clinical trials evaluating efficacy of new therapeutics.
Methods
Study participants: Georgian cohort. Fifty-one HIV-negative subjects between 23 and 83 years of age with LTBI or with pulmonary ATB disease were recruited in the metropolitan Atlanta area. Twenty-six ATB patients were included in the study, derived from a total of 86 patients with suspected pulmonary ATB enrolled at Grady Memorial Hospital prior to initiation of anti-TB treatment (Figure 1) . Diagnosis of pulmonary ATB (n = 26) was based on clinical parameters and sputum-positive status by AFB smear, amplified mycobacterium tuberculosis direct (MTD), and culture (Supplemental Table  1 ). Two patients were followed longitudinally for 9 months and successfully completed the 6-month standard regimen for drug-susceptible TB, which consisted of 2 months of HRZE, followed by 4 months of HR. Anti-TB treatment was provided according to CDC guidelines (50) . Resolution of TB was assessed by clinical, radiological, and microbiological criteria, as described in Supplemental Table 1 . Twenty-five healthy subjects from Atlanta were identified as having LTBI by a positive ESAT6-CFP10-specific IFN-γ ELISPOT assay, as described previously (18) . These individuals were all HIV-negative nonsmokers with no recent history of severe respiratory disease and had normal chest x-rays. The presence of CD4 + IFN-γ + T cells in PBMCs from both ATB and LTBI groups was assessed by flow cytometry and intracellular to more rapidly identify delayed responsiveness or nonresponsiveness to anti-TB treatment (e.g., in patients infected with drug-resistant strains) compared with sputum culture and may predict sputum conversion. In this regard, it has recently been suggested that the coexpression of HLA-DR + Ki-67 + on Mtb and purified protein derivative-specific (PPD-specific) CD4 + T cells predicts the time of sputum culture conversion in patients with MDR-TB (48) . Notably, CD38
+ IFN-γ + , HLA-DR + IFN-γ + , and Ki-67 + IFN-γ + T cell frequencies were below the discriminatory cutoffs for ATB and LTBI after 4 months of anti-TB treatment in our study; it is interesting to speculate that 4 months of anti-TB treatment may be sufficient for some patients with drug-suscep- Flow cytometry and staining. For ICS, cryopreserved PBMCs were rested overnight at 37°C, 5% CO 2 , in RPMI 1640 medium (Lonza) containing 10% FBS, 2 mM glutamine, 100 IU/ml penicillin, and 100 μg/ ml streptomycin. The viability of the lymphocytes was 75% to 95%. PBMCs (1 to 2 × 10 6 ) were each stimulated with CW antigens (10 μg/ ml) and ESAT6 and CFP10 peptide pools (10 μg/ml) for 2 hours followed by the addition of Brefeldin A (10 μg/ml) (BD Biosciences) and further incubated for 16 hours. PBMCs were stained for dead cells with LIVE/DEAD Fixable Yellow Dead Cell Stain (Life Technologies) at the beginning and then surface stained with appropriate antibodies: CD4 PerCp-Cy5.5 (clone L200), CD8 V500 (clone SK1), HLA-DR PE-Cy7 (clone L243), all from BD Biosciences; CD38 ECD (clone LS198. Statistics. Statistical analyses were performed using Graphpad Prism 5.0 software. The Mann-Whitney U test was used to compare 2 groups. The median was used for descriptive statistics for each parameter. Differences between paired samples were analyzed using the Wilcoxon matched-paired rank test. A P value of less than 0.05 was considered to be statistically significant. To evaluate the performance of each candidate biomarker in discriminating between ATB and LTBI groups and to establish probability cutoff values, logistic regression analysis was performed followed by ROC curve analysis, which plots sensitivity (true-positive rates) versus 1-specificity (false-positive rates). The AUC is a quantitative measure of the discrimination power of each biomarker between ATB and LTBI subjects and was calculated cytokine staining (ICS) following stimulation with Mtb-CW antigens and ESAT6 and CFP10 peptide pools. Out of the 26 ATB patients, 2 did not show reactivity to ESAT6/CFP10 peptide pools and were excluded from the study analysis ( Figure 1 ).
Study participants: South African cohort. Thirty-six HIV-negative subjects between 18 and 64 years of age with LTBI or with pulmonary ATB were recruited in the Western Cape province of South Africa at the South African Tuberculosis Vaccine Initiative (SATVI) field site in the Worcester area (Supplemental Table 3 ). Subjects with LTBI were identified as healthy, asymptomatic individuals (defined as individuals with negative symptom screening for all of the following TB-associated symptoms: persistent cough, fever, night sweats, weight loss, and hemoptysis) with a positive IGRA and with no previous history of TB diagnosis or treatment. All patients with pulmonary ATB had either a positive sputum AFB smear, a positive sputum culture for Mtb, or both, and had a clinical diagnosis of TB. In those with TB, peripheral blood was collected prior to starting standard anti-TB treatment. Samples that were shipped from Cape Town to Atlanta were selected based on availability of the number of vials of cells.
Sputum AFB smear microscopy, microbiological culture, and nucleic acid amplification assessments. Diagnosis of ATB was based on a positive AFB culture of processed sputum on Middlebrook 7H11 media and the BacT/Alert mycobacterial culture system (BioMerieux) for baseline isolates of Mtb. Culture conversion was defined as the first negative sputum culture with at least 1 subsequent negative culture and no subsequent positive results. Detection of AFB in sputum smears was conducted by direct fluorescent microscopy. If AFB smear was positive, the amplified MTD test (GeneProbe Hologic) was performed for direct detection of Mtb. All samples were processed for culture.
PBMC isolation, antigens, and peptides for cell stimulations. Blood samples from the Georgian cohort were collected from all subjects at baseline and longitudinal time points. PBMCs were isolated from blood as described previously (18) using cell preparation tubes (CPT, BD Biosciences) and cryopreserved in 90% fetal FBS (Hyclone) and 10% dimethyl sulfoxide (Sigma-Aldrich). PBMCs from the South African cohort were isolated using Ficoll-Hypaque (Sigma-Aldrich) in South Africa and cryopreserved at -180°C anywhere from 4 months 
